2025-12-19 - Analysis Report
Okay, here's a comprehensive analysis of TG Therapeutics (TGTX) based on the data you provided.

**1. Return Rate Comparison:**

*   **Company Overview:** TG Therapeutics Inc. is a biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases.
*   **TGTX Cumulative Return:** 66.26%
*   **VOO Cumulative Return:** 99.09%
*   **Divergence:** -28.8
*   **Relative Divergence:** 17.8
*   **Analysis:** TGTX has underperformed the S&P 500 (VOO) over the period examined. The divergence is currently at -28.8, which is relatively low within its historical range (relative divergence of 17.8).

**Alpha, Beta Analysis:**

| Year       | CAGR    | MDD  | Alpha    | Beta    | Cap(B) |
|------------|---------|------|----------|---------|--------|
| 2015-2017  | -5.0%   | 73.5% | -33.0%   | -0.0   | 1.3    |
| 2016-2018  | -12.0%  | 73.5% | -27.0%   | -0.0   | 0.7    |
| 2017-2019  | 74.0%   | 74.1% | 52.0%    | 0.0   | 1.8    |
| 2018-2020  | 316.0%  | 74.1% | 293.0%   | 0.1   | 8.3    |
| 2019-2021  | 124.0%  | 74.1% | 78.0%    | 0.3   | 3.0    |
| 2020-2022  | -71.0%  | 77.8% | -71.0%   | -0.0   | 1.9    |
| 2021-2023  | -284.0% | 77.8% | -285.0%  | -1.1   | 2.7    |
| 2022-2024  | 56.0%   | 77.8% | 36.0%    | -1.0   | 4.8    |
| 2023-2025  | 67.0%   | 80.7% | 3.0%     | -0.1   | 4.8    |

*   **CAGR:**  Shows fluctuating annual growth, with significant highs and lows, indicating volatility.
*   **MDD:** High Maximum Drawdown figures (above 70%) across all periods suggest substantial risk and price volatility.
*   **Alpha:** The Alpha is mostly negative, especially in recent years, suggesting underperformance relative to a benchmark after accounting for risk. Periods with positive Alpha (2017-2021) were followed by significant underperformance.
*   **Beta:** Beta values are close to 0 or negative, especially in recent years. This suggests that the stock has been less correlated with the overall market and may even move inversely to it.
*   **Cap:** Market Cap has fluctuated, with periods of growth followed by declines, reflecting the company's changing valuation.

**2. Recent Stock Price Fluctuations:**

*   **Current Close:** 29.93
*   **Previous Close:** 31.13
*   **Change:** -3.85%
*   **5-day SMA:** 30.92
*   **20-day SMA:** 31.38
*   **60-day SMA:** 33.11
*   **Analysis:** The current price is below all three moving averages, indicating a short-term downward trend. The recent price drop suggests increased selling pressure.

**3. Technical Indicators & Expected Return:**

*   **MRI:** 0.7 (Medium Investment)
*   **RSI:** 31.96 (Approaching oversold territory)
*   **PPO:** -0.0399 (Negative, indicating a downward trend)
*   **Hybrid Signal:** Buy (100% of cash, Very Safe)
*   **Recent Divergence Change:** 0.8 (+), suggesting a short-term upward correction.
*   **Expected Return:** -127.3% (Significantly negative, implying potential for substantial losses if held long-term).
*   **Analysis:** The MRI suggests a medium level of investment risk. The RSI indicates the stock is nearing oversold conditions, which *could* precede a rebound. However, the PPO and Expected Return paint a bearish picture. The Hybrid Signal suggests a "Buy" recommendation.

**4. Recent News & Significant Events:**

*   **[2025-11-03] The Earnings Caveat That Sent This Hot Biotech Diving:** This headline indicates negative sentiment related to earnings, likely contributing to a price decline.
*   **[2025-12-18] Why TGTX stock is trending among retail traders:**  While the headline sounds positive, the context ("2025 AllTime Highs & Verified Technical Trade Signals") suggests this is related to trading activity and technical analysis, not necessarily fundamental strength.
*   **[2025-11-28] TG Therapeutics schedules Dec. 2 fireside chat at Evercore event:** This is a neutral event, providing an opportunity for management to communicate with investors.
*   **[2025-11-17] TG Therapeutics: Positives From Q3'25 Earnings, But Competitors Progressing:** This headline suggests a mixed picture: some positives from earnings, but increasing competition.
*   **[2025-12-06] TG Therapeutics Stock Drop Looks Sharp, But How Deep Can It Go?:** This indicates ongoing concern about the stock's downward trajectory.
*   **[2025-10-27] TG Therapeutics (TGTX) Earnings Expected to Grow: What to Know Ahead of Q3 Release:** This suggests anticipation of positive earnings, but the later news indicates that the actual results (or caveats within them) were not well-received.

**4-2. Analyst Opinions:**

*   **Consensus:** Neutral (no clear buy/sell consensus).
*   **Target Price:** Average of $44.29 (suggests potential upside, but with a wide range of opinions: $13.00 - $60.00).
*   **Recent Rating Changes:** No recent rating changes were provided.
*   **Analysis:** Analyst opinions are mixed, with a wide range of target prices, indicating uncertainty about the stock's future performance.

**5. Recent Earnings Analysis:**

| 날짜        | EPS  | 매출       |
|-------------|------|------------|
| 2025-11-05 | 2.69 | 0.16 B$    |
| 2025-08-08 | 0.19 | 0.14 B$    |
| 2025-05-09 | 0.03 | 0.12 B$    |
| 2024-11-07 | 0.03 | 0.08 B$    |
| 2025-11-05 | 0.03 | 0.08 B$    |

*   **Analysis:** Revenue and EPS have generally been increasing over the past year. 2025-11-05 numbers appear to be outliers (either duplicate or a large increase in EPS). The positive EPS figures suggest profitability, which could be a positive sign.

**6. Financial Information:**

**Revenue and Profitability:**

| Quarter      | Revenue   | Profit Margin |
|--------------|-----------|---------------|
| 2025-09-30   | $0.16B    | 82.63%        |
| 2025-06-30   | $0.14B    | 86.58%        |
| 2025-03-31   | $0.12B    | 87.14%        |
| 2024-12-31   | $0.11B    | 85.77%        |
| 2024-09-30   | $0.08B    | 88.86%        |

**Capital and Profitability:**

| Quarter      | Equity    | ROE   |
|--------------|-----------|-------|
| 2025-09-30   | $0.61B    | 64.37% |
| 2025-06-30   | $0.28B    | 10.20% |
| 2025-03-31   | $0.24B    | 2.13%  |
| 2024-12-31   | $0.22B    | 10.49% |
| 2024-09-30   | $0.19B    | 2.02%  |

*   **Analysis:** Revenue has been consistently growing, and profit margins are exceptionally high, which is a positive sign. Equity has also increased significantly, especially in the most recent quarter. The high ROE in 2025-09-30 quarter suggests efficient use of equity to generate profits.

**7. Comprehensive Analysis (Summary):**

*   **Performance:** TGTX has underperformed the S&P 500, exhibiting high volatility and negative alpha in recent periods.
*   **Technicals:** The stock is currently in a short-term downtrend, with the price below key moving averages. The RSI suggests it's approaching oversold territory.
*   **News Sentiment:** Recent news is mixed, with concerns about earnings caveats and stock drops outweighing positive expectations.
*   **Analyst Opinion:** Analyst opinions are divided, with a wide range of target prices, reflecting uncertainty.
*   **Financials:** Revenue and profit margins are strong and growing, but equity and ROE fluctuate.
*   **Overall:** TGTX presents a mixed investment picture. While the recent financial performance shows strength, the stock's volatility, underperformance relative to the market, and negative expected return suggest significant risks. The high profit margins and revenue growth are positive signals, but the inconsistency in EPS and recent stock drop needs to be considered.

**In conclusion, investing in TGTX at this point appears to be high-risk. Potential investors should carefully consider the factors above, perform thorough due diligence, and be prepared for significant price swings.**


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.